| Diabetes Mellitus, Non-Insulin-Dependent
Basaglar vs Caduet
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Basaglar vs Caduet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCaduet has a higher rate of injection site reactions vs Basaglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Caduet but not Basaglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Basaglar
Caduet
At A Glance
SC injection
Once daily
Long-acting insulin analog
Oral
Daily
Calcium channel blocker + HMG-CoA reductase inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
- Hyperlipidemia
- Heterozygous familial hypercholesterolemia [HeFH]
- Homozygous familial hypercholesterolemia [HoFH]
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Coronary heart disease
Dosing
Type 1 Diabetes Mellitus Approximately one-third of total daily insulin requirements SC once daily; short- or rapid-acting pre-meal insulin covers the remainder.
Diabetes Mellitus, Non-Insulin-Dependent 0.2 units/kg or up to 10 units SC once daily.
Hypertensive disease Amlodipine 5 mg orally once daily (initial); max 10 mg once daily; start at 2.5 mg in elderly, fragile, small adult, pediatric (>6 years), or patients with hepatic insufficiency.
Stable angina, Angina Pectoris, Variant Amlodipine 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary Artery Disease Amlodipine 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent, Coronary heart disease Atorvastatin 10-80 mg orally once daily; start at 40 mg if LDL-C reduction >45% is required.
Heterozygous familial hypercholesterolemia [HeFH] Atorvastatin 10-80 mg orally once daily in adults; 10-20 mg once daily in pediatric patients >=10 years.
Homozygous familial hypercholesterolemia [HoFH] Atorvastatin 10-80 mg orally once daily in adults and pediatric patients >=10 years; starting dose 10-20 mg once daily.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in BASAGLAR
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to amlodipine, atorvastatin, or any excipient in CADUET, including reactions such as anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
Adverse Reactions
Most common (>=5%) Infection, nasopharyngitis, upper respiratory tract infection
Serious Severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Medication errors (accidental administration of rapid-acting insulin instead of insulin glargine), localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection site changes
Most common Edema, dizziness, flushing, palpitations, nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Rhabdomyolysis, myositis, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, gynecomastia
Pharmacology
Insulin glargine is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, providing sustained glucose-lowering activity over 24 hours with no pronounced peak.
CADUET combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance and blood pressure, with atorvastatin, a selective, competitive HMG-CoA reductase inhibitor that lowers plasma cholesterol by reducing cholesterol synthesis in the liver and increasing hepatic LDL receptor expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Basaglar
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (0/12)
Caduet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Basaglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Caduet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Basaglar
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Caduet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Basaglar.
No savings programs available for Caduet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BasaglarView full Basaglar profile
CaduetView full Caduet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.